CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of
investigational RNA interference (RNAi) therapeutics, today announced
that Douglas M. Fambrough, Ph.D., president and chief executive officer,
will present at the Jefferies 2016 Healthcare Conference. The
presentation will take place on Thursday, June 9, 2016 at 1:30 p.m. ET
at the Grand Hyatt in New York City.
A live webcast of the presentation can be accessed by visiting "Events
& Presentations" in the Investors & Media section on the
Company's website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is an RNA interference-based
biopharmaceutical company focused on the discovery and development of
innovative treatments for rare, inherited diseases involving the liver,
for other therapeutic areas in which the liver plays a key role, and for
cancers that are genetically defined. The Company is using its
proprietary RNA interference (RNAi) technology platform to build a broad
pipeline in these therapeutic areas. In many cases, Dicerna is pursuing
targets that have historically been difficult to inhibit using
conventional approaches, but where connections between targets and
diseases are well understood and documented. The Company intends to
discover, develop, and commercialize these novel therapeutics either on
its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160602006219/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media